Early responsiveness to continuous erythropoietin receptor activator predicts renal prognosis and is determined by a novel antioxidative marker in non-dialysis chronic kidney disease: a prospective, observational, single-center study
Sign Up to like & getrecommendations! Published in 2020 at "Clinical and Experimental Nephrology"
DOI: 10.1007/s10157-020-01873-0
Abstract: Background Responsiveness to erythropoietin-stimulating agents (ESAs) is important for anemia management in chronic kidney disease (CKD). We assessed the effects of a continuous erythropoietin receptor activator (CERA) on renoprotection beyond anemia management and the correlation… read more here.
Keywords: responsiveness cera; continuous erythropoietin; chronic kidney; cera ... See more keywords
Successful Treatment of Antibody-mediated Pure Red Cell Aplasia Induced by Continuous Erythropoietin Receptor Activator with Prednisolone.
Sign Up to like & getrecommendations! Published in 2021 at "Internal medicine"
DOI: 10.2169/internalmedicine.8823-21
Abstract: Pure red cell aplasia (PRCA) associated with erythropoiesis-stimulating agents (ESAs), which were first reported in 1998, usually occurs with subcutaneous administration of epoetin alfa (Eprex®). Improvements in ESA storage, handling, and administration methods have reduced… read more here.
Keywords: continuous erythropoietin; red cell; cell aplasia; pure red ... See more keywords